L
Lin Shen
Researcher at Peking University
Publications - 64
Citations - 9838
Lin Shen is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 30 publications receiving 6769 citations. Previous affiliations of Lin Shen include Peking Union Medical College.
Papers
More filters
Journal ArticleDOI
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang,Eric Van Cutsem,A. Feyereislova,Hyun Cheol Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,G. Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang +15 more
TL;DR: Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y. Janjigian,Yelena Y. Janjigian,Kohei Shitara,Markus Moehler,Marcelo Garrido,Pamela Salman,Lin Shen,Lucjan Wyrwicz,Kensei Yamaguchi,Tomasz Skoczylas,Arinilda Silva Campos Bragagnoli,Tianshu Liu,Michael Schenker,Patricio Eduardo Yanez,Mustapha Tehfe,Ruben Dario Kowalyszyn,Michalis V. Karamouzis,Ricardo Bruges,Thomas Zander,Roberto Pazo-Cid,Erika Hitre,Kynan Feeney,James M. Cleary,Valerie Poulart,Dana Cullen,Ming Lei,H. Xiao,Kaoru Kondo,M. Li,Jaffer A. Ajani +29 more
TL;DR: The CheckMate 649 trial as discussed by the authors evaluated first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophage alogaryal adenocarcinoma.
Journal ArticleDOI
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun,Lin Shen,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,Jean-Philippe Metges,Zhigang Li,Sung Bae Kim,Byoung Chul Cho,Wasat Mansoor,Shau-Hsuan Li,Patrapim Sunpaweravong,Maria Alsina Maqueda,Eray Goekkurt,Hiroki Hara,Luis Carlos Moreira Antunes,Christos Fountzilas,Akihito Tsuji,Victor Castro Oliden,Qi Liu,Sukrut Shah,Pooja Bhagia,Ken Kato,Keynote Investigators +25 more
TL;DR: In this paper, the authors compared pembrolizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced oesophageal cancer and Siewert type 1 gastro-oesophagesphageal junction cancer.
Journal ArticleDOI
Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study
Atsushi Ohtsu,Jaffer A. Ajani,Yu Xian Bai,Yung-Jue Bang,Hyun Cheol Chung,Hong Ming Pan,Tarek Sahmoud,Lin Shen,Kun-Huei Yeh,Keisho Chin,Kei Muro,Yeul Hong Kim,D. R. Ferry,Niall C. Tebbutt,Salah-Eddin Al-Batran,Heind Smith,Chiara Costantini,Syed Rizvi,David Lebwohl,Eric Van Cutsem +19 more
TL;DR: Compared with BSC, everolimus did not significantly improve overall survival for advanced gastric cancer that progressed after one or two lines of previous systemic chemotherapy and the safety profile observed for Everolimus was consistent with that observed forEverolimus in other cancers.
Journal ArticleDOI
Management of gastric cancer in Asia: resource-stratified guidelines
Lin Shen,Yan Shen Shan,Huang Ming Hu,Timothy J. Price,Bhawna Sirohi,Kun-Huei Yeh,Yi-Hsin Yang,Takeshi Sano,Han-Kwang Yang,Xiaotian Zhang,Sook Ryun Park,Masashi Fujii,Yoon-Koo Kang,Li-Tzong Chen,Li-Tzong Chen +14 more
TL;DR: This work aims to provide a stepwise strategy for management of gastric cancer applicable to different levels of health-care resources in Asian countries, using the categories of basic, limited, enhanced, and maximum level.